Glucagon-like peptide-1 analogues: An overview
Abnormalities of the incretin axis have been implicated in the pathogenesis of type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) and gastroinhibitory intestinal peptide constitutes >90% of all the incretin function. Augmentation of GLP-1 results in improvement of beta cell health in a glu...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2013-01-01
|
| Series: | Indian Journal of Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | http://www.ijem.in/article.asp?issn=2230-8210;year=2013;volume=17;issue=3;spage=413;epage=421;aulast=Gupta |
| _version_ | 1818899749997117440 |
|---|---|
| author | Vishal Gupta |
| author_facet | Vishal Gupta |
| author_sort | Vishal Gupta |
| collection | DOAJ |
| description | Abnormalities of the incretin axis have been implicated in the pathogenesis of type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) and gastroinhibitory intestinal peptide constitutes >90% of all the incretin function. Augmentation of GLP-1 results in improvement of beta cell health in a glucose-dependant manner (post-prandial hyperglycemia) and suppression of glucagon (fasting hyperglycemia), amongst other beneficial pleiotropic effects. Native GLP-1 has a very short plasma half-life and novel methods have been developed to augment its half life, such that its anti-hyperglycemic effects can be exploited. They can be broadly classified as exendin-based therapies (exenatide, exenatide once weekly), DPP-4-resistant analogues (lixisenatide, albiglutide), and analogues of human GLP-1 (liraglutide, taspoglutide). Currently, commercially available analogues are exenatide, exenatide once weekly, and liraglutide. This review aims to provide an overview of most GLP-1 analogues. |
| first_indexed | 2024-12-19T19:52:55Z |
| format | Article |
| id | doaj.art-3ae47a5170114ca5896027f08f61207a |
| institution | Directory Open Access Journal |
| issn | 2230-8210 2230-9500 |
| language | English |
| last_indexed | 2024-12-19T19:52:55Z |
| publishDate | 2013-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Endocrinology and Metabolism |
| spelling | doaj.art-3ae47a5170114ca5896027f08f61207a2022-12-21T20:07:53ZengWolters Kluwer Medknow PublicationsIndian Journal of Endocrinology and Metabolism2230-82102230-95002013-01-0117341342110.4103/2230-8210.111625Glucagon-like peptide-1 analogues: An overviewVishal GuptaAbnormalities of the incretin axis have been implicated in the pathogenesis of type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) and gastroinhibitory intestinal peptide constitutes >90% of all the incretin function. Augmentation of GLP-1 results in improvement of beta cell health in a glucose-dependant manner (post-prandial hyperglycemia) and suppression of glucagon (fasting hyperglycemia), amongst other beneficial pleiotropic effects. Native GLP-1 has a very short plasma half-life and novel methods have been developed to augment its half life, such that its anti-hyperglycemic effects can be exploited. They can be broadly classified as exendin-based therapies (exenatide, exenatide once weekly), DPP-4-resistant analogues (lixisenatide, albiglutide), and analogues of human GLP-1 (liraglutide, taspoglutide). Currently, commercially available analogues are exenatide, exenatide once weekly, and liraglutide. This review aims to provide an overview of most GLP-1 analogues.http://www.ijem.in/article.asp?issn=2230-8210;year=2013;volume=17;issue=3;spage=413;epage=421;aulast=GuptaExenatideglucagon-like-peptideGLP-analoguesincretinsincretin-mimeticsliraglutide |
| spellingShingle | Vishal Gupta Glucagon-like peptide-1 analogues: An overview Indian Journal of Endocrinology and Metabolism Exenatide glucagon-like-peptide GLP-analogues incretins incretin-mimetics liraglutide |
| title | Glucagon-like peptide-1 analogues: An overview |
| title_full | Glucagon-like peptide-1 analogues: An overview |
| title_fullStr | Glucagon-like peptide-1 analogues: An overview |
| title_full_unstemmed | Glucagon-like peptide-1 analogues: An overview |
| title_short | Glucagon-like peptide-1 analogues: An overview |
| title_sort | glucagon like peptide 1 analogues an overview |
| topic | Exenatide glucagon-like-peptide GLP-analogues incretins incretin-mimetics liraglutide |
| url | http://www.ijem.in/article.asp?issn=2230-8210;year=2013;volume=17;issue=3;spage=413;epage=421;aulast=Gupta |
| work_keys_str_mv | AT vishalgupta glucagonlikepeptide1analoguesanoverview |